Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

Fig. 3

The SUCRA plots of efficacies and toxicities of different CCRT regimens. A The SUCRA plots of efficacies of different CCRT regimens. B The SUCRA plots of toxicities of different CCRT regimens. SUCRA curve was used to compare the SUCRA value of different CCRT regimens to ascertain the efficacies or the toxicities ranks, the larger the SUCRA value, the better the efficacy or the lower the toxicity. A = CCRT (cisplatin + etoposide). B = CCRT (carboplatin + paclitaxel). C = CCRT (pemetrexed + carboplatin). CCRT = concurrent chemoradiotherapy. D = CCRT (pemetrexed + cisplatin). E = CCRT (docetaxel + cisplatin). F = CCRT (S-1 + cisplatin). G = CCRT (mitomycin + vindesine + cisplatin). H = CCRT (cisplatin + vinorelbine). I = CCRT (cisplatin). K = RT. L = CCRT (5-FU). M = CCRT (paclitaxel + cisplatin). N = CCRT (irinotecan + carboplatin). O = CCRT (nedaplatin). ORR = overall response rate. OS = overall survival. P = CCRT (carboplatin + etoposide). Q = CCRT (paclitaxel). R = CCRT (carboplatin). SUCRA = surface under the cumulative ranking

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us